Focus: Aytu BioPharma is a Denver-based public company operating in diagnostics and small molecules across gastroenterology, infectious diseases, and oncology. The company manages a portfolio of established branded drugs at peak lifecycle alongside early-stage diagnostic and specialty pharma programs.
Profile data last refreshed 16h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Aytu BioPharma to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Aytu BioPharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Lead branded product at peak lifecycle; proton-pump inhibitor for gastric acid suppression in parietal cells.
Help build intelligence for Aytu BioPharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Sedative hypnotic at peak sales; patent protection extends to August 2032, providing 6+ years of exclusivity runway.
ADHD treatment approaching loss of exclusivity; revenue erosion expected as generic competition intensifies.
Extended-release antihistamine with patent cliff in March 2029; portfolio diversification into allergy/antihistamine space.
2 discontinued, 0 duplicate formulations not shown
AYTU|Aytu Biopharma Inc|Price:2.230|Chg%:+0.080 - TradingKey
AYTU|Aytu Biopharma Inc|Price:2.230|Chg%:+0.080 TradingKey
Aytu BioPharma (AYTU) Edges Higher, Testing Key Resistance Levels - Breakout Stock Alerts - po-news-eg.net
Aytu BioPharma (AYTU) Edges Higher, Testing Key Resistance Levels - Breakout Stock Alerts po-news-eg.net
Aytu BioPharma to Present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026 - newswire.com
Aytu BioPharma to Present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026 newswire.com
Pharma firm Aytu BioPharma to present at virtual investor event May 28 - Stock Titan
Pharma firm Aytu BioPharma to present at virtual investor event May 28 Stock Titan
Aytu BioPharma to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026 - Weatherford Democrat
Aytu BioPharma to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026 Weatherford Democrat
Aytu BioPharma to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026 - ACCESS Newswire
Aytu BioPharma to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026 ACCESS Newswire
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo